Search results
Results from the WOW.Com Content Network
Etrolizumab was developed by Genentech [2] [3] by engineering the FIB504 antibody to include human IgGl-heavy chain and κ-light chain frameworks; it is manufactured in CHO cells. [4] As of 2016, it was in phase III studies for induction and maintenance therapy in people with ulcerative colitis and Crohn's.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Efalizumab (brand name Raptiva, Genentech, Merck Serono) is a formerly available medication designed to treat autoimmune diseases, originally marketed to treat psoriasis.As implied by the suffix -zumab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.
Category talk: Drugs developed by Genentech. ... Print/export Download as PDF; Printable version; In other projects ...
Genentech is a pioneering research-driven biotechnology company [14] that has continued to conduct R&D internally as well as through collaborations. [20] [21] Genentech's research collaborations include: In 2008 Genentech entered into a collaboration with Roche and its subsidiary GlycArt to develop obinutuzumab. [22]
Print/export Download as PDF; ... Drugs developed by Genentech (102 P) P. Genentech people (21 P) Pages in category "Genentech"
Amongst the earliest uses of biotechnology in pharmaceutical manufacturing is the use of recombinant DNA technology to modify Escherichia coli bacteria to produce human insulin, which was performed at Genentech in 1978. [1] Prior to the development of this technique, insulin was extracted from the pancreas glands of cattle, pigs, and other farm ...
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.